A0086 BCG plus mitomycin (BCG+MM) versus BCG-alone as adjuvant intravesical therapy for high-risk, Non-Muscle-Invasive Bladder Cancer (NMIBC): Effects on urinary symptoms and other aspects of Health-Related Quality of Life (HRQL) in a randomised trial (BCGMM, ANZUP 1301)

European Urology 2026

View at publisher
Authors: D. Hayne, A.Y. Zhang, H. Thomas, L. Krieger, J. Ischia, P. Anderson, R. Srivastav, W. Green, J. Grummet, P. Bastick, E. Beardsley, A. Blatt
+12 more M. Patel, A. Mitterdorfer, M. Roberts, S. Sengupta, M. Winter, L. Cheung, C. Hawks, A. Martin, SP McCombie, A.D. Redfern, I. Davis, M.R. Stockler
DOI: 10.1016/s0302-2838(26)00151-x
Cited by: 1

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Immune responses and vaccinations Urinary Bladder and Prostate Research

Publication details

Journal / source
European Urology
Publisher
Elsevier BV
Volume
89
Pages
S1–S2
Publication date
13 February 2026
Language
EN